Published: June 07, 2010
Wall Street Media Presents Eric Whitman, MD on Delcath's Positive Clinical Results
NEW YORK - (BUSINESS WIRE) - Wall Street Media presents an exclusive video of Dr. Eric Whitman, a
highly regarded surgical oncologist who specializes in melanoma and is
Director of the Atlantic Melanoma Center. Dr. Whitman attended the
American Society of Clinical Oncology's (ASCO) Annual Meeting, where he
took special note of a presentation on Delcath's (Nasdaq:DCTH) PHP
study. Dr. Whitman stresses that PHP has proven to be clinically
effective.
Please visit the following link to view the video:
http://wsmco.com/show.aspx?1661_Very_Positive_DCTH_Results
Delcath's PHP clinical trials have focused on a certain melanoma spread
to the liver.
Some key factors we think were overlooked or misunderstood in today's
market action are:
-
Survival rate tripled for cancer patients treated with PHP
(Percutaneous Hepatic Perfusion) - 398 days vs. 124 with best
alternative care
-
The data was even better than the initial press release from April.
The hepatic PFS (primary endpoint) was 245 days in the PHP arm and 49
days in the BAC (best alternative care) arm
-
$745 million is the estimate for peak annual U.S. sales, if PHP is
approved by the FDA
-
Potential increase to $5.6 billion if this treatment is used in
primary liver cancer as well as metastases from other types of cancer
We discuss the vast potential for Delcath's PHP system:
-
The majority of the cases are not in the US, 80% of liver cancer is
in Asia
-
The possibility for huge "off-label" use
-
The possibility for Delcath's PHP system to be used for many other
cancer treatments in future
On his blog at http://drericwhitman.wordpress.com/
Dr. Whitman states "There is no question in my mind that this is
clinically effective."
In another recent case of seriously misleading stock information, Todd
Sullivan of http://ValuePlays.net
shares the value he sees in ACAS (Nasdaq:ACAS) after their public
downgrade.
Please visit the following link to view the video:
http://wsmco.com/show.aspx?1658_Value_In_ACAS_Shares
Many Biotechs with positive news released today suffered in the general
market meltdown. VIVUS Inc. (Nasdaq:VVUS) who we also like
released positive Phase III data from The Revive Diabetes study for
product Avanafil. Nevertheless, their shares dropped $.41 today.
Please visit the following link to view the video:
http://wsmco.com/show.aspx?1654_Events_with_VVUS_and_DCTH
Follow and learn from Wall Street Media on StockTwits:
http://twitter.com/wsmco
Wall Street Media presents exclusive insights from the leading
transparent investors on the planet:
http://wsmco.com
After catching up on stock news and making money, visit DateTwit to send
a free smile or a virtual drink to anyone on Twitter without blowing
your social media capital:
www.DateTwit.com

Wall Street Media
Claire McCurry, 212-354-1102
Copyright © 2012, Business Wire, Inc., All rights reserved.
Copyright © 2012, NewsBlaze,
Daily News